Drug intelligence / Profile preview

ABT-560

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

ABT-560 is a small molecule neuronal nicotinic receptor (NNR) modulator that primarily targets the α4β2 and α5 subunits of the nicotinic acetylcholine receptor. It was developed for potential use in treating cognitive deficits and other central nervous system (CNS) disorders. The drug showed promise in preclinical models relevant to cognition but was discontinued after early clinical development. The mechanism of action involves modulation of specific neuronal nicotinic receptors implicated in cognitive function[1][2][3][4][5].

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on ABT-560.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-560.

Explore the full profile